文献速递乳腺癌放疗放疗物理与技术姑息放疗与转移瘤

螺旋断层放疗用于局部晚期或复发乳腺癌

Helical TomoTherapy for locally advanced or recurrent breast cancer.
PubMed 文献 · Radiat Oncol · 2017-01-28

回顾性分析26例接受螺旋断层放疗(HT)的大体积、不规则形乳腺癌患者,其中原发组14例、再程放疗组12例。中位PTV为2276 cm³,中位头尾方向长度为28 cm,中位PTV剂量40 Gy,HT均未中断完成,急性毒性轻至中度。原发组中位LRFS和OS分别为21和57个月,复发组分别为10和11个月。

要点

  • HT可对累及全半胸的大体积不规则乳腺癌靶区实施放疗且急性毒性可接受。
  • 原发组中位LRFS 21个月、OS 57个月,复发组中位LRFS 10个月、OS 11个月。
  • 中位PTV 2276 cm³、头尾方向长度28 cm,中位PTV剂量40 Gy。

核心结论

  • HT对累及大范围胸部的晚期靶区可行,急性毒性可接受,原发和姑息适应症均可考虑。

研究设计与样本

  • 回顾性分析26例接受HT的大体积、不规则形乳腺癌患者,原发组14例、再程放疗组12例。
  • 复发组既往接受过大量系统治疗,肿瘤伴广泛皮肤浸润,多累及完整半胸。
  • 原发组照射锁骨上、锁骨下、腋窝及胸骨旁淋巴结区,11例联合化疗。

主要发现

  • 中位PTV为2276 cm³(范围1476-6837 cm³),中位头尾方向长度为28 cm(范围15-52 cm)。
  • 中位PTV剂量为40 Gy(范围32-60 Gy),所有患者均未中断完成HT。
  • 急性毒性为轻至中度。
  • 原发组放疗后中位LRFS和OS分别为21和57个月,复发组分别为10和11个月。
  • 原发组中位PFS为18个月,复发组为7个月。

临床怎么用

  • 对累及大范围胸部、形态不规则的局部晚期或复发乳腺癌,可考虑采用HT实施放疗。
  • 基于治疗体积和解剖情况,HT可用于原发根治性及再程放疗/姑息适应症。

局限性

  • 本研究为回顾性分析,样本量26例,原发组与复发组例数少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report our experience of using helical tomotherapy (HT) to treat large and irregular shaped loco-regional advanced breast cancer target volumes embracing various organs at risk. PATIENTS AND METHODS: We retrospectively analyzed 26 patients treated for very large, irregular shaped breast cancers. Patients were treated either with the intent to achieve local control in a primary setting (n = 14) or in a reirradiation setting (n = 12). The recurrence group was heavily pretreated with systemic therapy. Tumors were characterized by wide infiltration of the skin, encompassing mostly a complete hemithorax. The primary group underwent irradiation of supraclavicular, infraclavicular, axillary and parasternal lymphonodal region. Radiotherapy was combined with chemotherapy (n = 11). We assessed the PTV volume and its craniocaudal extension, the dose to the organs at risk, acute toxicity and survival. RESULTS: Median PTV was 2276 cm3 (1476-6837 cm3) with a median cranio-caudal extension of 28 cm (15-52 cm). The median dose to PTV was 40 Gy (32-60Gy). HT could be carried out in all patients without interruption. The acute toxicities were mild to moderate. The median LRFS and OS after radiotherapy was 21 and 57 months for the primary group versus 10 and 11 months for the recurrence group. Median PFS was 18 months (primary group) and 7 months (recurrence group). CONCLUSIONS: HT is feasible for advanced thorax embracing target volumes with acceptable acute toxicity. Both curative and palliative indications can be considered good indications based on treatment volume and anatomical constellation.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Duma MN, Heinrich C, Schönknecht C, et al. Helical TomoTherapy for locally advanced or recurrent breast cancer. Radiat Oncol. 2017. PMID: 28129767. doi:10.1186/s13014-016-0736-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。